Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, has expanded its drug product (DP) services offering by adding a new facility for quality control and bioanalytics at its DPS site in Basel (CH) to support its global DP capacity increase.    The expansion includes 6000m2 of state-of-the-art labs and office space to support early and late-stage clinical and commercial DP QC. The new facility allows DPS to double its capacity for the development and ...